Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338894 | 0.88 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL7331767 | 0.87 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL7445885 | 0.83 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL2568273 | 0.79 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL7331051 | 0.78 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL3549366 | 0.77 | DHFR (0.52) | — | |
| SCHEMBL7329483 | 0.77 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL5493178 | 0.77 | PPARG (0.63) | PPARGPPARA | |
| SCHEMBL7333238 | 0.77 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL2578739 | 0.77 | PPARG (0.60) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996009818-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EMESIS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | claimed |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20210205415-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC | 2021-07-08 | — | — | US | disclosed |
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20020013304-A1 | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | VIVUS INC. | 2002-01-31 | — | — | US | disclosed |
| US-5767310-A | Phenoxyphenylacetic acid derivatives | MERCK & CO., INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0774965-A4 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO INC (US) | 1997-10-29 | — | — | EP | disclosed |
| US-5668176-A | ENDOTHELIN ANTAGONIST | MERCK & CO. INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0774965-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO. INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5565485-A | TREATING CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996009818-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EMESIS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996004905-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| WO-1994021590-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0617001-A1 | Phenoxyphenylacetic acid derivatives | MERCK & CO. INC. (US) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | PPARG 2279/4885PPARA 1405/4885 |
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | PPARG 2279/4885PPARA 1405/4885 |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | PPARG 2331/4885PPARA 1129/4885 |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | PPARG 2279/4885PPARA 1405/4885 |
| US-20020013304-A1 | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | SHBG, GNRHR, FSHR | PPARG 437/4885PPARA 429/4885 |
| US-20210205415-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | PPARG 2331/4885PPARA 1129/4885 |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | SCTR, GIPR, APLNR | PPARG 2331/4885PPARA 1129/4885 |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | PPARG 2279/4885PPARA 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.